Exploristics is pleased to announce its involvement with the COVASE trial evaluating cystic fibrosis drug, Dornase alfa, as a treatment for COVID-19 being run by University College London and the Francis Crick Institute. Support for the COVASE study design and protocol was provided by Exploristics with funding provided by LifeArc.
To support the study, Exploristics conducted a literature review to gather information on the options for the primary endpoint and performed further evaluation to select a clinically relevant endpoint that gave the best chance of success. Given the need for urgency in a rapidly evolving situation, Exploristics explored a range of design options that would generate clinical evidence in the most efficient way. This led to the implementation of a novel design which integrated historical control data with data from a prospectively designed randomised, controlled study.
Find out more: